Hematological Department, People's Hospital of Jiangsu Province
Nanjing, Jiangsu, 210029, China
Location status: Recruiting
Recruiting
NCT Number: NCT05967949
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
The study design belongs to a retrospective study, collecting information on patients with PTCL who were diagnosed and treated with chidamide as maintenance therapy at our center. The collected data includes age, gender, previous treatment regimens, results of auxiliary examinations (such as blood routine, biochemistry, bone marrow cytology, pathology, flow cytometry, NGS, etc.), as well as PET-CT images. The safety and efficacy of Chidemide as first-line maintenance therapy in PTCL will be analyzed.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- (1) Age: 18 years and older; (2) Gender: Male/Female; (3) Diagnosed with PTCL; (4) Received chidamide as maintenance therapy after first-line treatment.
Exclusion criteria
- (1) Patients with other types of lymphomas; (2) Pregnant women.
Treatment and study plan
Chidamide
DrugThis subset of patients received chidamide as first-line maintenance therapy.
Primary outcomes
-
PFS
Time frame: 2 years
progression free survival
Secondary outcomes
-
OS
Time frame: 2 years
overall survival
-
CR
Time frame: 2 years
complete remission
-
DOR
Time frame: 2 years
duration of remission
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Other
Registry information
Official study title
A Retrospective (Non-interventional) Clinical Study on the First-line Maintenance Treatment of Peripheral T-cell Lymphoma (PTCL) With Chidamide.
Important dates
- Study start
- 2023
- Primary completion
- 2026
- Study completion
- 2028
- First posted
- Aug 1, 2023
- Registry last updated
- Aug 1, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
NCT06874946
Hematologic Diseases, Hemic and Lymphatic Diseases
Beijing, Beijing Municipality, China
View Trial Details
Recruiting
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
NCT04747236
PTCL
Long Beach, California, United States
View Trial Details
Not Yet Recruiting
SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)
NCT07725705
First Line Treatment, PTCL
View Trial Details
Not Yet Recruiting
A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.
NCT07657572
Hemic and Lymphatic Diseases, Immune System Diseases
View Trial Details